## Su-Jin Park

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6661697/publications.pdf

Version: 2024-02-01

52 papers	2,799 citations	22 h-index	197818 49 g-index
54	54	54	6123
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host and Microbe, 2020, 27, 704-709.e2.	11.0	815
2	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	12.8	224
3	Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clinical Microbiology and Infection, 2020, 26, 1520-1524.	6.0	180
4	Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea. Clinical Infectious Diseases, 2016, 62, 755-760.	5.8	165
5	Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infectious Diseases, 2019, 19, 676.	2.9	144
6	Pathobiological features of a novel, highly pathogenic avian influenza A(H5N8) virus. Emerging Microbes and Infections, 2014, 3, $1-13$ .	6.5	106
7	Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 2268.	2.4	106
8	Ferret animal model of severe fever with thrombocytopenia syndrome phlebovirus for human lethal infection and pathogenesis. Nature Microbiology, 2019, 4, 438-446.	13.3	66
9	Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus (SFTSV) in South Korea. JCI Insight, 2020, 5, .	5.0	58
10	Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors. Journal of Virology, 2015, 89, 287-299.	3.4	54
11	Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerging Microbes and Infections, 2021, 10, 152-160.	6.5	54
12	Molecular genomic characterization of tick- and human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea. PLoS Neglected Tropical Diseases, 2017, 11, e0005893.	3.0	54
13	Virulence and Genetic Compatibility of Polymerase Reassortant Viruses Derived from the Pandemic (H1N1) 2009 Influenza Virus and Circulating Influenza A Viruses. Journal of Virology, 2011, 85, 6275-6286.	3.4	51
14	Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets. Nature Communications, 2019, 10, 3836.	12.8	51
15	Epidemiology of severe fever and thrombocytopenia syndrome virus infection and the need for therapeutics for the prevention. Clinical and Experimental Vaccine Research, 2018, 7, 43.	2.2	47
16	Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis. Nature Microbiology, 2019, 4, 429-437.	13.3	46
17	Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. Eurosurveillance, 2017, 22, .	7.0	44
18	Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. Nature Communications, 2021, 12, 4567.	12.8	43

#	Article	IF	CITATIONS
19	Dynamic changes in host gene expression associated with H5N8 avian influenza virus infection in mice. Scientific Reports, 2015, 5, 16512.	3.3	40
20	Comparison of the pathogenic potential of highly pathogenic avian influenza (HPAI) H5N6, and H5N8 viruses isolated in South Korea during the 2016–2017 winter season. Emerging Microbes and Infections, 2018, 7, 1-10.	6.5	32
21	Development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thermal inactivation method with preservation of diagnostic sensitivity. Journal of Microbiology, 2020, 58, 886-891.	2.8	28
22	Cross-genotype protection of live-attenuated vaccine candidate for severe fever with thrombocytopenia syndrome virus in a ferret model. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26900-26908.	7.1	25
23	Molecular Signatures of Inflammatory Profile and B-Cell Function in Patients with Severe Fever with Thrombocytopenia Syndrome. MBio, 2021, 12, .	4.1	25
24	Genetic and phylogenetic characterizations of a novel genotype of highly pathogenic avian influenza (HPAI) H5N8 viruses in 2016/2017 in South Korea. Infection, Genetics and Evolution, 2017, 53, 56-67.	2.3	23
25	Seroprevalence and genetic characterization of severe fever with thrombocytopenia syndrome virus in domestic goats in South Korea. Ticks and Tick-borne Diseases, 2018, 9, 1202-1206.	2.7	21
26	Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production. Journal of General Virology, 2013, 94, 1230-1235.	2.9	20
27	Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets. Scientific Reports, 2015, 5, 15940.	3.3	20
28	Pathogenicity and genetic characterisation of a novel reassortant, highly pathogenic avian influenza (HPAI) H5N6 virus isolated in Korea, 2017. Eurosurveillance, 2018, 23, .	7.0	19
29	Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. Journal of Virology, 2017, 91, .	3.4	18
30	Greater Efficacy of Black Ginseng (CJ EnerG) over Red Ginseng against Lethal Influenza A Virus Infection. Nutrients, 2019, 11, 1879.	4.1	18
31	Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology, 2016, 498, 36-43.	2.4	16
32	Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. Journal of General Virology, 2014, 95, 793-798.	2.9	15
33	Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness. Journal of Microbiology and Biotechnology, 2018, 28, 997-1006.	2.1	15
34	Comparison of the virulence and transmissibility of canine H3N2 influenza viruses and characterization of their canine adaptation factors. Emerging Microbes and Infections, 2018, 7, 1-14.	6.5	14
35	Shedding and Transmission Modes of Severe Fever With Thrombocytopenia Syndrome Phlebovirus in a Ferret Model. Open Forum Infectious Diseases, 2019, 6, .	0.9	14
36	Rapid acquisition of polymorphic virulence markers during adaptation of highly pathogenic avian influenza H5N8 virus in the mouse. Scientific Reports, 2017, 7, 40667.	3.3	13

#	Article	IF	CITATIONS
37	Altered virulence of Highly Pathogenic Avian Influenza (HPAI) H5N8 reassortant viruses in mammalian models. Virulence, 2018, 9, 133-148.	4.4	13
38	Evaluation of the zoonotic potential of a novel reassortant H1N2 swine influenza virus with gene constellation derived from multiple viral sources. Infection, Genetics and Evolution, 2015, 34, 378-393.	2.3	11
39	Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Archives of Virology, 2016, 161, 2749-2764.	2.1	11
40	Genetic diversity and pathogenic potential of low pathogenic H7 avian influenza viruses isolated from wild migratory birds in Korea. Infection, Genetics and Evolution, 2016, 45, 268-284.	2.3	10
41	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	3.4	10
42	A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus. MBio, 2019, 10, .	4.1	10
43	Injectable and Pathogenâ€Mimicking Hydrogels for Enhanced Protective Immunity against Emerging and Highly Pathogenic Influenza Virus. Small, 2016, 12, 6279-6288.	10.0	8
44	Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea. Frontiers in Microbiology, 2020, 11, 587613.	3.5	8
45	Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine. Clinical and Experimental Vaccine Research, 2014, 3, 194.	2.2	7
46	Growth and Pathogenic Potential of Naturally Selected Reassortants after Coinfection with Pandemic H1N1 and Highly Pathogenic Avian Influenza H5N1 Viruses. Journal of Virology, 2016, 90, 616-623.	3.4	4
47	Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Phlebovirus in Domesticated Deer in South Korea. Virologica Sinica, 2019, 34, 501-507.	3.0	4
48	Avian-derived NS gene segments alter pathogenicity of the A/Puerto Rico/8/34 virus. Virus Research, 2014, 179, 64-72.	2.2	3
49	Evaluation of two different enzyme-linked immunosorbent assay for severe fever with thrombocytopenia syndrome virus diagnosis. Clinical and Experimental Vaccine Research, 2018, 7, 82.	2.2	3
50	Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets. Journal of Microbiology, 2019, 57, 163-169.	2.8	3
51	Adjuvant efficacy of mOMV against avian influenza virus infection in mice. Journal of Microbiology, 2013, 51, 682-688.	2.8	2
52	Walled-off Pancreatic necrosis in a Dog. Journal of Veterinary Clinics, 2018, 35, 146-149.	0.1	2